The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 22, 2022

Filed:

Sep. 04, 2019
Applicant:

China Pharmaceutical University, Nanjing, CN;

Inventors:

Qidong You, Nanjing, CN;

Zhengyu Jiang, Nanjing, CN;

Yan Wang, Nanjing, CN;

Yuhui Jin, Nanjing, CN;

Mengchen Lu, Nanjing, CN;

Xiaoli Xu, Nanjing, CN;

Xiaoke Guo, Nanjing, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/655 (2006.01); A61K 47/55 (2017.01); A61K 47/54 (2017.01); A61P 35/02 (2006.01); A61K 31/506 (2006.01); A61K 41/00 (2020.01);
U.S. Cl.
CPC ...
A61K 31/655 (2013.01); A61K 31/506 (2013.01); A61K 41/0023 (2013.01); A61K 47/54 (2017.08); A61K 47/55 (2017.08); A61P 35/02 (2018.01);
Abstract

It discloses a proteolysis targeting chimeric molecule, a preparation method and an application thereof. The proteolysis targeting chimeric molecule provided by the disclosure can inhibit the expression of BCR-ABL and/or CRBN protein in BCR-ABL and/or CRBN positive leukemia K562 cells to varying degrees, and thus can be used to prepare drugs for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule with n=3 has excellent photo-isomerization activity, and can be used in preparation of the reagents or drugs for light-regulated degradation of BCR-ABL and/or CRBN protein. The disclosure also provides a method for synthesizing the series of proteolysis targeting chimeric molecules.


Find Patent Forward Citations

Loading…